Singapore, Nov. 2 -- Merck, a leading science and technology company, has opened its new Asia-Pacific Bioprocessing Production Centre in Daejeon, South Korea. The centre represents an investment of mo... Read More
Singapore, Nov. 2 -- A new Singapore study found that around one in six (16.7%) higher-risk patients with hormone receptor-positive (HR+), HER2-negative early breast cancer whose cancer had not spread... Read More
Singapore, Oct. 30 -- US-based BioMarin Pharmaceutical Inc. has entered into an exclusive worldwide license agreement with South Korea-based GC Biopharma Corp. and Hanmi Pharm Co., to develop and comm... Read More
Singapore, Oct. 30 -- Japan-based Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately JPY 1.06 billion ($6.8 million) in nine R&D projects for the develop... Read More
Singapore, Oct. 30 -- Australia-based Firebrick Pharma has announced the launch of its third product in the Nasodine range: Nasodine(R) Sinus Rinse. The product recently completed production and comme... Read More
Singapore, Oct. 30 -- Waters Corporation has announced AI-Powered Peak Integration, the next step in its strategy to build intelligent AI, machine learning, and automation cloud-based capabilities dir... Read More
Singapore, Oct. 30 -- DKSH has signed an agreement to acquire 100% of NewBridge Pharmaceuticals, a Dubai-headquartered healthcare commercialisation platform with operations across 14 markets in the ME... Read More
Singapore, Oct. 29 -- Brain-computer interfaces (BCIs) are entering a new phase of technological development, moving beyond experimental demonstrations towards practical applications that could transf... Read More
Singapore, Oct. 29 -- PeptiDream Inc., a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development of peptide- based therapeutics and PDRadiopharma Inc., a wh... Read More
Singapore, Oct. 29 -- Japan-based Astellas Pharma Inc. has entered into an exclusive option and license agreement for DAX-044, Audax's lead immuno-oncology AVIKINE(R) candidate. Under the agreement, ... Read More